{"id":"amibegron-sr58611a","safety":{"commonSideEffects":[{"rate":"null","effect":"Dysuria"},{"rate":"null","effect":"Urinary retention"},{"rate":"null","effect":"Urinary tract infection"}]},"_chembl":{"chemblId":"CHEMBL1193948","moleculeType":"Small molecule","molecularWeight":"403.91"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It acts by stimulating the beta-3 adrenergic receptors in the bladder, leading to increased bladder capacity and reduced urge to urinate. This results in improved symptoms of overactive bladder.","oneSentence":"Amibegron is a beta-3 adrenergic receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:28.603Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Symptomatic treatment of overactive bladder"}]},"trialDetails":[{"nctId":"NCT00855530","phase":"PHASE3","title":"Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-09","conditions":"Major Depressive Disorders","enrollment":527},{"nctId":"NCT00432614","phase":"PHASE3","title":"Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-01","conditions":"Major Depressive Disorder","enrollment":510},{"nctId":"NCT00385307","phase":"PHASE3","title":"Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Major Depressive Disorder","enrollment":680},{"nctId":"NCT00825058","phase":"PHASE3","title":"Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Major Depressive Disorders","enrollment":317},{"nctId":"NCT00825019","phase":"PHASE3","title":"Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-09","conditions":"Major Depressive Disorders","enrollment":306},{"nctId":"NCT00252356","phase":"PHASE3","title":"Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-09","conditions":"Major Depressive Disorder","enrollment":468},{"nctId":"NCT00252330","phase":"PHASE3","title":"Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-09","conditions":"Major Depressive Disorder","enrollment":476},{"nctId":"NCT00252343","phase":"PHASE3","title":"Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-09","conditions":"Anxiety Disorder","enrollment":360},{"nctId":"NCT00345098","phase":"PHASE3","title":"A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Depressive Disorder, Major Depression","enrollment":704},{"nctId":"NCT00397098","phase":"PHASE3","title":"Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-11","conditions":"Anxiety Disorders","enrollment":257},{"nctId":"NCT00535340","phase":"PHASE3","title":"An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Anxiety Disorders","enrollment":55},{"nctId":"NCT00319709","phase":"PHASE3","title":"An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-04","conditions":"Depressive Disorder","enrollment":288},{"nctId":"NCT00266747","phase":"PHASE3","title":"An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-12","conditions":"Anxiety Disorders","enrollment":366},{"nctId":"NCT00332891","phase":"PHASE3","title":"An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-03","conditions":"Anxiety Disorders","enrollment":508}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"amibegron (SR58611A)","genericName":"amibegron (SR58611A)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amibegron is a beta-3 adrenergic receptor agonist. Used for Symptomatic treatment of overactive bladder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}